Artiva Biotherapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Artiva Biotherapeutics Inc.
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
SAN Diego
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
ARTV
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001817241
EIN
86-3614316

Board of directors

Follow this board

Chief executives

Fred Aslan · President and CEO
Dates unknown

Director election results

Annual meeting of September 8, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

7 of this board's directors also sit on 28 other boards.

Network of Artiva Biotherapeutics Inc.'s board connections Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Bicara Therapeutics Inc. Bicara Therapeutics In... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. Janux Therapeutics Inc. Janux Therapeutics Inc... LENZ Therapeutics Inc. LENZ Therapeutics Inc. Mineralys Therapeutics Inc. Mineralys Therapeutics... Nkarta Inc. Nkarta Inc. Parabilis Medicines Inc. Parabilis Medicines In... PepGen Inc. PepGen Inc. Laura Stoppel Laura Stoppel Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Artiva Biotherapeutics Inc...
Shared director Other board Same sector +12 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$109,120,138
21 purchases by 5 insiders
Sold, last 12 months
$1,943,096
15 sales by 5 insiders
Date Insider Transaction Shares Price Value
Sep 15, 2026 Fred Aslan Director, Officer (Chief Executive Officer) Grant or award +110,000 — —
Sep 10, 2026 Fred Aslan Director, Officer (Chief Executive Officer) Grant or award +45,000 — —
Sep 9, 2026 Banerjee Subhashis Officer (Chief Medical Officer) Grant or award +30,000 — —
Sep 9, 2026 Bush Jennifer Officer (COO, CLO, Compliance Officer) Grant or award +45,000 — —
Sep 9, 2026 Horan Christopher Officer (Chief Tech Operations Officer) Grant or award +40,000 — —
Sep 9, 2026 Gines Diego Miralles Officer (President & Head of R&D) Grant or award +45,000 — —
Sep 8, 2026 Fred Aslan Director, Officer (Chief Executive Officer) Open-market sale −23,429 $10.92 $255,746
Sep 3, 2026 Fred Aslan Director, Officer (Chief Executive Officer) Open-market sale −61,888 $11.16 $690,392
Sep 3, 2026 Banerjee Subhashis Officer (Chief Medical Officer) Open-market sale −1,100 $11.16 $12,271
Sep 3, 2026 Bush Jennifer Officer (COO, CLO, Compliance Officer) Open-market sale −8,391 $11.16 $93,606
Sep 3, 2026 Horan Christopher Officer (Chief Tech Operations Officer) Open-market sale −10,366 $11.16 $115,638
Aug 27, 2026 Banerjee Subhashis Officer (Chief Medical Officer) Option exercise +5,306 $1.92 $10,188
Aug 27, 2026 Banerjee Subhashis Officer (Chief Medical Officer) Open-market sale −8,222 $12.01 $98,736
Aug 18, 2026 Banerjee Subhashis Officer (Chief Medical Officer) Option exercise +429 $1.92 $824
Aug 18, 2026 Banerjee Subhashis Officer (Chief Medical Officer) Open-market sale −429 $12.00 $5,148

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.